Can you provide a dot phrase for diabetes management that includes lifestyle counseling, baseline labs, metformin initiation, criteria for adding second‑line agents, and follow‑up recommendations?

Diabetes Management Dot Phrase

Start metformin 500-850 mg once or twice daily with meals alongside comprehensive lifestyle modification (diet and exercise) as first-line therapy for most patients with type 2 diabetes, unless they have established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease—in which case initiate a GLP-1 receptor agonist or SGLT-2 inhibitor with or without metformin based on glycemic needs. 1

Initial Assessment & Baseline Labs

Before initiating therapy, obtain:

• Estimated glomerular filtration rate (eGFR) – metformin is contraindicated if eGFR <30 mL/min/1.73 m² and not recommended for initiation if eGFR 30-45 mL/min/1.73 m² 2
• Hemoglobin A1C
• Fasting lipid panel
• Liver function tests
• Complete blood count (to establish baseline for B12 monitoring)
• Urine albumin-to-creatinine ratio
• Cardiovascular risk assessment

Lifestyle Counseling Components

Provide specific guidance on:

• Physical activity: At least 150 minutes/week of moderate-intensity aerobic exercise plus at least 2 sessions/week of resistance training involving large muscle groups 3
• Dietary modification: Focus on weight loss if overweight/obese
• Smoking cessation: Include counseling and pharmacotherapy as routine component of care 3
• Alcohol limitation: Counsel against excessive intake due to increased lactic acidosis risk with metformin 2

Metformin Initiation Protocol

Starting dose: 500 mg once daily or 500-850 mg twice daily with meals 2

• Take with meals to minimize gastrointestinal side effects (diarrhea, nausea, upset stomach) 2
• Titrate gradually over several weeks to minimize GI intolerance
• Target dose: 2000 mg daily in divided doses for optimal efficacy
• Swallow tablets whole

Key Metformin Warnings & Monitoring

Contraindications 2:

• eGFR <30 mL/min/1.73 m²
• Acute or chronic metabolic acidosis
• Hypersensitivity to metformin

Ongoing monitoring:

• Check eGFR at least annually (more frequently in elderly or those at risk for renal impairment) 2
• Assess vitamin B12 levels periodically due to risk of deficiency 2
• Monitor for lactic acidosis symptoms: malaise, myalgias, respiratory distress, somnolence, abdominal pain 2

Temporary discontinuation required for:

• Surgical procedures
• Radiological procedures with iodinated contrast
• Severe dehydration, infection, or hemodynamic instability 2

Criteria for Adding Second-Line Agents

Do not delay treatment intensification if A1C goals not met within 3 months 1. Add second agent based on:

High-Risk Comorbidities (Prioritize These)

If patient has established ASCVD, high CV risk, heart failure, or CKD, add:

• GLP-1 receptor agonist (preferred for ASCVD) 1
• SGLT-2 inhibitor (preferred for heart failure or CKD) 1

These agents should be initiated with or without metformin based on glycemic needs and can be considered as initial therapy in these high-risk populations 1.

Standard Glycemic Control

If A1C remains >7% (or individualized target) after 3 months on metformin:

• Add GLP-1 receptor agonist or SGLT-2 inhibitor as preferred second-line agents 1
• Consider early combination therapy at diagnosis if A1C >9% to extend time to treatment failure 1

Severe Hyperglycemia

If A1C >10% (86 mmol/mol) or glucose >300 mg/dL with symptoms or weight loss:

• Initiate insulin early while continuing metformin 1
• Consider adding GLP-1 receptor agonist to insulin regimen for greater efficacy 1

Follow-Up Schedule

• Every 3 months until A1C at goal, then every 6 months 1
• At each visit: Review medication adherence, assess for side effects, check A1C, evaluate for complications
• Reassess medication regimen every 3-6 months and adjust based on efficacy, tolerability, and patient-centered factors 1
• Annual comprehensive diabetes evaluation including renal function, lipids, retinal exam, foot exam

Common Pitfalls to Avoid

• Therapeutic inertia: Do not delay intensification beyond 3 months if not at goal 1
• Continuing metformin with declining renal function: Discontinue if eGFR falls below 30; reassess benefit/risk if eGFR 30-45 2
• Missing high-risk patients: Screen for ASCVD, heart failure, and CKD at diagnosis—these patients benefit from GLP-1 RA or SGLT-2i as initial or early add-on therapy 1
• Ignoring GI side effects: If metformin intolerance occurs, consider dose reduction, extended-release formulation, or alternative first-line agent 2
• Forgetting to continue metformin with insulin: Maintain metformin when starting insulin for ongoing metabolic benefits unless contraindicated 1